VivoSeq
Other

Antiplatelet Therapy

0

Pipeline Programs↗

10

Active Trials↗

2

Companies Involved↗

Antiplatelet Therapy is an early-stage landscape with 0 programs across 2 companies. The most active players are Bristol-Myers Squibb, Jiangsu vcare pharmaceutical technology co., LTD.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalJ

Jiangsu vcare pharmaceutical technology co., LTD

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

36

clinical trials

Completed16 · 44%
Unknown status8 · 22%
Not yet recruiting5 · 14%
Recruiting4 · 11%
Terminated1 · 3%
Suspended1 · 3%
Other1 · 3%

Clinical Trials

Trial Activity

36 trials

Short Versus Long Antiplatelet Therapy After TAVI
Recruiting·UUniversity Hospital, Caen·Phase 3·NCT06518317·1,400 enrolled
Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting
Recruiting·FFirst Affiliated Hospital of Zhejiang University·N/A·NCT04694248·172 enrolled
Optimal PERioperative Antiplatelet Therapy Investigation ON Abdominal Surgery After Coronary Stent Implantation
Recruiting·KKyoto University·Phase 4·NCT06723145·1,200 enrolled
Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE Trial
Recruiting·YYonsei University·N/A·NCT05320926·3,744 enrolled
A Randomized Comparison of CLOpidogrel Monotherapy Versus Extended Dual-antiplatelet Therapy Beyond 12 Months After Implantation of Drug-eluting StEnts in High-risk Lesions or Patients; A-CLOSE Trial
Active, not recruiting·YYonsei University·Phase 4·NCT03947229·3,200 enrolled
Colonoscopy and Antiplatelet Therapy Trial
Not yet recruiting·OOchsner Health System·Phase 4·NCT06613191·100 enrolled
The Bridging Antiplatelet Therapy With Cangrelor 2 Study
Not yet recruiting·UUniversity of Florida·Phase 4·NCT07225842·50 enrolled
24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial
Not yet recruiting·YYonsei University·N/A·NCT04989257·3,488 enrolled
Discontinuation of Antiplatelet Therapy After Drug-Coated Balloon Treatment
Not yet recruiting·UUlsan University Hospital·N/A·NCT07398001·1,042 enrolled
Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
Not yet recruiting·LLepu Medical Technology (Beijing) Co., Ltd.·N/A·NCT04995159·2,150 enrolled
Platelet-dependent Thrombosis: a Placebo-controlled Trial of Antiplatelet Therapy (Clopidogrel)
Completed·NNewcastle-upon-Tyne Hospitals NHS Trust·Phase 4·NCT00728156·90 enrolled
Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation
Completed·SShenyang Northern Hospital·Phase 4·NCT01094457·840 enrolled
Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT00827411·2,500 enrolled
Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT01538446·880 enrolled
Optimal antiPlatelet Therapy for High Bleeding and Ischemic RISK Patients Trial
Completed·SShenyang Northern Hospital·Phase 4·NCT03431142·7,758 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)